Seres Therapeutics Updates Principal Executive Office Address

Ticker: MCRB · Form: 8-K · Filed: Jan 9, 2024 · CIK: 1609809

Seres Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanySeres Therapeutics, Inc. (MCRB)
Form Type8-K
Filed DateJan 9, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: administrative, corporate-governance

TL;DR

**Seres Therapeutics just moved offices, no big deal for the stock.**

AI Summary

Seres Therapeutics, Inc. filed an 8-K on January 9, 2024, primarily to update its principal executive offices from 200 Sidney Street, 4th Floor, Cambridge, MA 02139 to 101 Cambridgepark Drive, Cambridge, MA 02140. This change, effective on the filing date, is a routine administrative update. For investors, this filing indicates no operational or financial shifts, merely a change in the company's physical address, which typically has no direct impact on stock value.

Why It Matters

This filing is a routine administrative update regarding Seres Therapeutics' physical address and does not signal any operational changes or financial events that would directly impact the company's stock performance.

Risk Assessment

Risk Level: low — The filing only reports a change in the company's business address, which is a standard administrative update with no inherent financial risk.

Analyst Insight

Smart investors would note this as a routine administrative update with no material impact on the company's operations or financial health, thus requiring no immediate investment action.

Key Players & Entities

  • Seres Therapeutics, Inc. (company) — the registrant filing the 8-K
  • January 9, 2024 (date) — date of earliest event reported and filing date
  • 101 Cambridgepark Drive, Cambridge, MA 02140 (address) — new principal executive offices
  • 200 Sidney Street - 4th Floor, Cambridge, MA 02139 (address) — former principal executive offices
  • MCRB (company) — trading symbol for Seres Therapeutics, Inc.

FAQ

What is the primary purpose of this 8-K filing by Seres Therapeutics, Inc.?

The primary purpose of this 8-K filing is to report a change in the principal executive offices of Seres Therapeutics, Inc. from 200 Sidney Street - 4th Floor, Cambridge, MA 02139 to 101 Cambridgepark Drive, Cambridge, MA 02140.

When did the change in Seres Therapeutics, Inc.'s principal executive offices become effective?

The change in Seres Therapeutics, Inc.'s principal executive offices became effective on January 9, 2024, which is stated as the 'Date of earliest event reported'.

What is the trading symbol for Seres Therapeutics, Inc.?

The trading symbol for Seres Therapeutics, Inc. is MCRB, and its common stock is registered on The Nasdaq Stock Market LLC (Nasdaq Global Select Market).

Under which SEC Act is this current report filed?

This current report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

What was Seres Therapeutics, Inc.'s former address?

Seres Therapeutics, Inc.'s former address was 200 Sidney Street - 4th Floor, Cambridge, MA 02139.

Filing Stats: 588 words · 2 min read · ~2 pages · Grade level 10 · Accepted 2024-01-09 07:05:34

Key Financial Figures

  • $0.001 — ich registered Common stock, par value $0.001 per share MCRB The Nasdaq Stock Mar

Filing Documents

01. Regulation FD Disclosure

Item 7.01. Regulation FD Disclosure. On January 9, 2024, Seres Therapeutics, Inc. (the "Company") posted an updated corporate presentation in the "Investors and News" portion of its website at www.serestherapeutics.com . A copy of the slide presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information in Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. The Company undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit 99.1.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. The following Exhibit 99.1 relates to Item 7.01 and shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Seres Therapeutics, Inc. Corporate Presentation as of January 2024 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 9, 2024 SERES THERAPEUTICS, INC. By: /s/ Thomas J. DesRosier Name: Thomas J. DesRosier Title: Chief Legal Officer and Executive Vice President

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.